Optimized sequential therapy < em > vs < /em > 10- and 14-d concomitant therapy for eradicating < em > Helicobacter pylori < /em > : A randomized clinical trial
CONCLUSION: The optimized 14-d sequential therapy is a safe and effective alternative. Its eradication rate is comparable to that of the 14-d concomitant therapy while causing fewer AEs and allowing a gain in terms of cost.PMID:38463026 | PMC:PMC10921140 | DOI:10.3748/wjg.v30.i6.556 (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - March 11, 2024 Category: Gastroenterology Authors: Hassan Seddik Jihane Benass Sanaa Berrag Asmae Sair Reda Berraida Hanae Boutallaka Source Type: research
Optimized sequential therapy < em > vs < /em > 10- and 14-d concomitant therapy for eradicating < em > Helicobacter pylori < /em > : A randomized clinical trial
CONCLUSION: The optimized 14-d sequential therapy is a safe and effective alternative. Its eradication rate is comparable to that of the 14-d concomitant therapy while causing fewer AEs and allowing a gain in terms of cost.PMID:38463026 | PMC:PMC10921140 | DOI:10.3748/wjg.v30.i6.556 (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - March 11, 2024 Category: Gastroenterology Authors: Hassan Seddik Jihane Benass Sanaa Berrag Asmae Sair Reda Berraida Hanae Boutallaka Source Type: research
Optimized sequential therapy < em > vs < /em > 10- and 14-d concomitant therapy for eradicating < em > Helicobacter pylori < /em > : A randomized clinical trial
CONCLUSION: The optimized 14-d sequential therapy is a safe and effective alternative. Its eradication rate is comparable to that of the 14-d concomitant therapy while causing fewer AEs and allowing a gain in terms of cost.PMID:38463026 | PMC:PMC10921140 | DOI:10.3748/wjg.v30.i6.556 (Source: World Journal of Gastroenterology)
Source: World Journal of Gastroenterology - March 11, 2024 Category: Gastroenterology Authors: Hassan Seddik Jihane Benass Sanaa Berrag Asmae Sair Reda Berraida Hanae Boutallaka Source Type: research
Optimized sequential therapy < em > vs < /em > 10- and 14-d concomitant therapy for eradicating < em > Helicobacter pylori < /em > : A randomized clinical trial
CONCLUSION: The optimized 14-d sequential therapy is a safe and effective alternative. Its eradication rate is comparable to that of the 14-d concomitant therapy while causing fewer AEs and allowing a gain in terms of cost.PMID:38463026 | PMC:PMC10921140 | DOI:10.3748/wjg.v30.i6.556 (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - March 11, 2024 Category: Gastroenterology Authors: Hassan Seddik Jihane Benass Sanaa Berrag Asmae Sair Reda Berraida Hanae Boutallaka Source Type: research
Optimized sequential therapy < em > vs < /em > 10- and 14-d concomitant therapy for eradicating < em > Helicobacter pylori < /em > : A randomized clinical trial
CONCLUSION: The optimized 14-d sequential therapy is a safe and effective alternative. Its eradication rate is comparable to that of the 14-d concomitant therapy while causing fewer AEs and allowing a gain in terms of cost.PMID:38463026 | PMC:PMC10921140 | DOI:10.3748/wjg.v30.i6.556 (Source: World Journal of Gastroenterology)
Source: World Journal of Gastroenterology - March 11, 2024 Category: Gastroenterology Authors: Hassan Seddik Jihane Benass Sanaa Berrag Asmae Sair Reda Berraida Hanae Boutallaka Source Type: research
Optimized sequential therapy < em > vs < /em > 10- and 14-d concomitant therapy for eradicating < em > Helicobacter pylori < /em > : A randomized clinical trial
CONCLUSION: The optimized 14-d sequential therapy is a safe and effective alternative. Its eradication rate is comparable to that of the 14-d concomitant therapy while causing fewer AEs and allowing a gain in terms of cost.PMID:38463026 | PMC:PMC10921140 | DOI:10.3748/wjg.v30.i6.556 (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - March 11, 2024 Category: Gastroenterology Authors: Hassan Seddik Jihane Benass Sanaa Berrag Asmae Sair Reda Berraida Hanae Boutallaka Source Type: research
Optimized sequential therapy < em > vs < /em > 10- and 14-d concomitant therapy for eradicating < em > Helicobacter pylori < /em > : A randomized clinical trial
CONCLUSION: The optimized 14-d sequential therapy is a safe and effective alternative. Its eradication rate is comparable to that of the 14-d concomitant therapy while causing fewer AEs and allowing a gain in terms of cost.PMID:38463026 | PMC:PMC10921140 | DOI:10.3748/wjg.v30.i6.556 (Source: World Journal of Gastroenterology)
Source: World Journal of Gastroenterology - March 11, 2024 Category: Gastroenterology Authors: Hassan Seddik Jihane Benass Sanaa Berrag Asmae Sair Reda Berraida Hanae Boutallaka Source Type: research
Optimized sequential therapy < em > vs < /em > 10- and 14-d concomitant therapy for eradicating < em > Helicobacter pylori < /em > : A randomized clinical trial
CONCLUSION: The optimized 14-d sequential therapy is a safe and effective alternative. Its eradication rate is comparable to that of the 14-d concomitant therapy while causing fewer AEs and allowing a gain in terms of cost.PMID:38463026 | PMC:PMC10921140 | DOI:10.3748/wjg.v30.i6.556 (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - March 11, 2024 Category: Gastroenterology Authors: Hassan Seddik Jihane Benass Sanaa Berrag Asmae Sair Reda Berraida Hanae Boutallaka Source Type: research
Optimized sequential therapy < em > vs < /em > 10- and 14-d concomitant therapy for eradicating < em > Helicobacter pylori < /em > : A randomized clinical trial
CONCLUSION: The optimized 14-d sequential therapy is a safe and effective alternative. Its eradication rate is comparable to that of the 14-d concomitant therapy while causing fewer AEs and allowing a gain in terms of cost.PMID:38463026 | PMC:PMC10921140 | DOI:10.3748/wjg.v30.i6.556 (Source: World Journal of Gastroenterology)
Source: World Journal of Gastroenterology - March 11, 2024 Category: Gastroenterology Authors: Hassan Seddik Jihane Benass Sanaa Berrag Asmae Sair Reda Berraida Hanae Boutallaka Source Type: research
Optimized sequential therapy < em > vs < /em > 10- and 14-d concomitant therapy for eradicating < em > Helicobacter pylori < /em > : A randomized clinical trial
CONCLUSION: The optimized 14-d sequential therapy is a safe and effective alternative. Its eradication rate is comparable to that of the 14-d concomitant therapy while causing fewer AEs and allowing a gain in terms of cost.PMID:38463026 | PMC:PMC10921140 | DOI:10.3748/wjg.v30.i6.556 (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - March 11, 2024 Category: Gastroenterology Authors: Hassan Seddik Jihane Benass Sanaa Berrag Asmae Sair Reda Berraida Hanae Boutallaka Source Type: research
Optimized sequential therapy < em > vs < /em > 10- and 14-d concomitant therapy for eradicating < em > Helicobacter pylori < /em > : A randomized clinical trial
CONCLUSION: The optimized 14-d sequential therapy is a safe and effective alternative. Its eradication rate is comparable to that of the 14-d concomitant therapy while causing fewer AEs and allowing a gain in terms of cost.PMID:38463026 | PMC:PMC10921140 | DOI:10.3748/wjg.v30.i6.556 (Source: World Journal of Gastroenterology)
Source: World Journal of Gastroenterology - March 11, 2024 Category: Gastroenterology Authors: Hassan Seddik Jihane Benass Sanaa Berrag Asmae Sair Reda Berraida Hanae Boutallaka Source Type: research
Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line Helicobacter pylori eradication: a real-world evidence study
CONCLUSIONS: The bismuth add-on increased the first-line H. pylori eradication rate of 2-week TPZ-based triple therapy.PMID:38459869 | DOI:10.1080/14787210.2024.2329251 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - March 9, 2024 Category: Infectious Diseases Authors: Jun-Hyung Cho Source Type: research
The multicenter real-world report of the efficacies of 14-day esomeprazole-based and rabeprazole-based high-dose dual therapy in first-line Helicobacter pylori eradication in Taiwan
CONCLUSIONS: Esomeprazole-based HDDT achieved over 90% eradication rates but rabeprazole-based HDDT, which failed.PMID:38461114 | DOI:10.1016/j.jmii.2024.02.009 (Source: Journal of Microbiology, Immunology, and Infection)
Source: Journal of Microbiology, Immunology, and Infection - March 9, 2024 Category: Microbiology Authors: Wei-Chen Tai I-Ting Wu Hsin-Ming Wang Pao-Yuan Huang Chih-Chien Yao Cheng-Kun Wu Shih-Cheng Yang Chih-Ming Liang Pin-I Hsu Seng-Kee Chuah Source Type: research
Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line Helicobacter pylori eradication: a real-world evidence study
CONCLUSIONS: The bismuth add-on increased the first-line H. pylori eradication rate of 2-week TPZ-based triple therapy.PMID:38459869 | DOI:10.1080/14787210.2024.2329251 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - March 9, 2024 Category: Infectious Diseases Authors: Jun-Hyung Cho Source Type: research
The multicenter real-world report of the efficacies of 14-day esomeprazole-based and rabeprazole-based high-dose dual therapy in first-line Helicobacter pylori eradication in Taiwan
CONCLUSIONS: Esomeprazole-based HDDT achieved over 90% eradication rates but rabeprazole-based HDDT, which failed.PMID:38461114 | DOI:10.1016/j.jmii.2024.02.009 (Source: Journal of Microbiology, Immunology, and Infection)
Source: Journal of Microbiology, Immunology, and Infection - March 9, 2024 Category: Microbiology Authors: Wei-Chen Tai I-Ting Wu Hsin-Ming Wang Pao-Yuan Huang Chih-Chien Yao Cheng-Kun Wu Shih-Cheng Yang Chih-Ming Liang Pin-I Hsu Seng-Kee Chuah Source Type: research
